Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool April 10, 2006 Rich Duprey	Merck Splits the Difference The pharmaceutical wins one, loses one in New Jersey Vioxx trials. Investors should expect to see more losses.
The Motley Fool August 2, 2007 Brian Orelli	98 Lawsuits Down, About 15,000 To Go Merck's Vioxx caseload just got a little smaller, when an appellate court ruled that 98 people from England and Wales could not sue in the U.S. Shares are up on the news.
The Motley Fool November 4, 2005 Rich Duprey	Merck Eases Its Pain The pharmaceutical giant wins an important Vioxx trial. And while it's a welcome reprieve for the company, the decision doesn't seem to warrant the enthusiasm with which the market greeted the decision.
The Motley Fool March 1, 2006 Rich Duprey	Celebrex Doubles Lawsuit Risk A new study says the Pfizer painkiller doubles the risk of a heart attack. Investors, beware.
The Motley Fool December 13, 2005 Rich Duprey	Merck's Bitter Pill The first federal Vioxx trial ends with a deadlocked jury, but that's not necessarily good news for the drugmaker, or investors.
The Motley Fool August 22, 2005 Stephen D. Simpson	Vioxx Brings the Pain A jury stings Merck for hefty Vioxx damages, battering shares.
The Motley Fool September 7, 2007 Billy Fisher	Epic Vioxx Victory for Merck Merck scores a major victory in its Vioxx saga in the courtroom as New Jersey's Supreme Court rules against the possibility of a national class action Vioxx lawsuit. Shares react positively.
The Motley Fool May 30, 2008 Brian Orelli	For Merck, Hindsight Hurts Even after dragging its feet for years, one has to wonder if Merck settled the Vioxx cases a little too quickly?
The Motley Fool May 21, 2008 Brian Orelli	OK, Last Vioxx Settlement, Honest! What's another $58 million when Merck's already forking over $4.85 billion?
The Motley Fool September 11, 2008 Brian Orelli	Vive le Vioxx Lawsuit Just when Merck thought it was finally done with lawsuits pertaining to Vioxx, it's gotten pulled back in.
The Motley Fool November 15, 2004 Mathew Emmert	Merck's Silver Lining The government joins the plethora of lawsuit filers, but Merck will survive. Still, the stock remains appropriate for only those investors with a high tolerance for risk and a long-term time horizon.
The Motley Fool September 18, 2007 Brian Orelli	New York Tag-Teams Merck Both the city and state of New York sue Merck over Vioxx payments, alleging the big pharma defrauded Medicaid and other government agencies, by hiding problems related to its painkilling drug.
BusinessWeek July 30, 2007	Another Risk Factor For Merck Plaintiffs' lawyers are salivating over evidence they hope could support their argument that even patients who used the painkiller for short periods were in danger.
The Motley Fool November 13, 2007 Brian Orelli	Merck: Case Closed? Now that Merck has settled its lawsuit, it can get back to business, focusing on continued growth from its cholesterol drugs, new diabetic medication, and cervical cancer vaccine. Investors, take note.
The Motley Fool August 26, 2005 Stephen D. Simpson	Merck Broaches the Obvious Merck will naturally end up settling many Vioxx cases, but the details are far from clear at this point. Investors, take note.
The Motley Fool June 23, 2005 Rich Smith	Dueling Fools: Merck Bull It's hard to argue with a price this cheap. With a price-to-free cash flow ratio of less than 11, Merck's a steal.
The Motley Fool October 24, 2005 Stephen D. Simpson	Merck Needs to Take Its Medicine It will be a long, long time before business at the pharmaceutical returns to business as usual. Turnarounds can pay off for patient investors.
The Motley Fool February 23, 2005 Stephen D. Simpson	Take Two on COX-2 FDA panel recommendations breathe new life into Merck and Pfizer's COX-2 pain medications. Looking ahead, investors should give a good, long look to the drug sector.
The Motley Fool June 23, 2005 Stephen D. Simpson	Dueling Fools: Merck Bear Looking at other big pharma peers, Merck is dead last when it comes to expected three- to five-year EPS growth. Why buy a troubled pharma when better options exist?
The Motley Fool October 23, 2006 Brian Lawler	Merck Mints Money The pharmaceutical hangs on, despite ongoing Vioxx woes. Conservative investors may do best to stay away from Merck until a lower share-price opportunity presents itself, now that shares are no longer sporting such a large Vioxx discount.
BusinessWeek December 5, 2005 Michael Orey	Presto: A New Vioxx Liability Estimate! Why analysts' reports shift wildly with every twist in litigation against Merck.
Chemistry World March 13, 2007	Vioxx Trial Blow for Merck A jury has awarded $47.5 million to an Idaho man after finding that the anti-inflammatory drug Vioxx, made by Merck and Co., Inc., contributed to his heart attack.
BusinessWeek September 5, 2005 Amy Barrett	The Pain Is Just Beginning Why the Vioxx debacle will hobble Merck for years to come
The Motley Fool April 17, 2007 Brian Lawler	Merck Raises the Earnings Roof Shares of Merck soar after it raises 2007 earnings guidance.
The Motley Fool January 25, 2005 Stephen D. Simpson	Prognosis Good for Merck The pharmaceutical weathered a tough year but should ride out its Vioxx troubles. While strict value investors may be put off, risk-tolerant investors can buy these shares today.
The Motley Fool October 23, 2007 Brian Orelli	Old Merck on New Drugs It looks like the old Merck is back, with new drugs driving double-digit sales growth in the third-quarter.
The Motley Fool February 21, 2006 Rick Aristotle Munarriz	Biggest Disappointment: Merck In the spirit of the Winter Olympics, here are stock challenges from the publication's writers: Merck is rich in cash, tradition, and potholes.
The Motley Fool December 21, 2006 Brian Lawler	Dueling Fools: Merck Bull Rebuttal Plenty of cash. Big pipeline. Not to worry. The future can't be predicted, but Merck's history shows its ability to weather even the toughest pharmaceutical-development environments.
Pharmaceutical Executive January 1, 2013	Product Liability Claims and Comment K Courts across the country are making it easier to prove that a drug is unsafe, warning label notwithstanding.
The Motley Fool November 8, 2004 Brian Gorman	Pfizer's Gloom Factor The stock will continue to be depressed, but things will improve if Celebrex's safety is proven.
The Motley Fool January 31, 2005 Stephen D. Simpson	Merck Takes Another Body Blow Loss of exclusivity on major osteoporosis drug could take steam out of the recovery process. Investors in Merck just can't catch a break.
BusinessWeek April 21, 2011 Tom Randall	Merck's Risky Bet on Research CEO Frazier, who made his name fighting drug lawsuits, is investing billions to churn out new medicines.
The Motley Fool March 3, 2010 Brian Orelli	Judge's Ruling Has Brand and Generic Drugmakers Smiling A ruling on the patents on Merck's blood pressure medications Cozaar and Hyzaar benefited both Merck and the plaintiff in the suit, generic-drug maker Teva Pharmaceuticals. The defendant in the suit wasn't actually Merck but the Food and Drug Administration.
The Motley Fool May 29, 2009 Brian Orelli	Merck's Bad News Nothing to Sneeze At The U.S. Patent and Trademark Office reexamination of Merck's patent on allergy medication, Singulair, is nothing to sneeze at. The $2.8 billion worth of Singulair that Merck sold in the U.S. last year made up 12% of its total pharmaceutical sales.
The Motley Fool May 5, 2010 Brian Orelli	Doubled Revenue, but Not High Growth An acquisition and some rearrangements make Merck's revenue line sound better than it is.
BusinessWeek July 25, 2005 Gene G. Marcial	Is Merck Rallying After That Nasty Tumble? Although most analysts who track Merck remain bearish on the beleaguered drugmaker, some upbeat investors are buying. Why? It's Vioxx market may have softened, but its new vaccines will rise to the occasion.
The Motley Fool September 30, 2004 W. D. Crotty	Merck Chokes Back Vioxx The $2.3 billion arthritis drug is withdrawn from the market after clinical studies point to dangerous side-effects. Despite the bad news, Merck's big dividend payouts don't appear to be in jeopardy at the moment.
The Motley Fool December 21, 2006 Ryan Fuhrmann	Dueling Fools: Merck Bear Investors, because of its recent run-up, the risk/reward tradeoff is not very compelling. There are safer, more lucrative ways to invest in the space.
The Motley Fool February 8, 2008 Brian Orelli	Merck in Lukewarm Water The pharmaceutical's settlement ends a government probe into Medicaid overcharging allegations.
Bio-IT World December 15, 2004 Kevin Davies	Patients Before Profits? After the Vioxx disaster, Pharma needs to reassure patients that they come first.
The Motley Fool June 23, 2005 Rich Smith	Dueling Fools: Merck Bull Rebuttal Priced at a P/E of 13 and paying you a 4.8% dividend, Merck isn't just affordable -- it's a stock you can't afford not to own.
The Motley Fool April 3, 2007 Brian Lawler	Merck Gets the Combo Merck gets marketing approval for a diabetes combination drug. Investors, take note.
The Motley Fool October 21, 2004 Brian Gorman	Merck Is Down But Not Out The pharma's woes may have silver linings. For now, the company's investors might want to sit tight.
BusinessWeek November 29, 2004 Carey & Barrett	Lessons From The Vioxx Fiasco What drugmakers, the FDA, doctors, and patients need to do.
The Motley Fool July 18, 2008 Brian Orelli	Foolish Forecast: How Quickly Can Merck Turn It Around? Views you can use to get clues on the news.
The Motley Fool December 21, 2006 Brian Lawler	Dueling Fools: Merck Bull What you are getting with Merck is one of the best-managed pharmas out there that will be experiencing solid double-digit earnings growth in the not-too-distant future with a smart dividend payout.
The Motley Fool March 9, 2009 Brian Orelli	Merck-Schering Trumps Pfizer-Wyeth The new Merck deal looks a lot better than a combined Pfizer plus Wyeth.
The Motley Fool January 26, 2006 Rich Duprey	Will Acquisitions Patch Merck's Pipeline? The pharmaceutical giant announces a biotech shopping spree. A few key acquisitions that contribute late-stage drugs and significant revenue might be all Merck needs to keep its pipeline open. Investors, take note.
BusinessWeek July 30, 2007 Arlene Weintraub	Is Merck's Medicine Working? Spurred by the Vioxx fiasco, CEO Clark is trying to revamp the drug giant's culture. Analysts expect Merck's top line to grow 4%, to $23.5 billion this year, an achievement considering that sales growth had flatlined even before Vioxx imploded.
The Motley Fool September 25, 2006 Brian Lawler	Merck's Positive Contribution Bad press from Vioxx shouldn't overshadow the company's new offering. Investors, take note.